Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation
| Autor: | Masayoshi Masuko, Tatsuya Suwabe, Kyoko Fuse, Yasuhiko Shibasaki, Shigeo Hashimoto, Hirohito Sone, Miwako Narita, Toshio Yano, Tomoyuki Tanaka, Takayuki Katagiri, Takashi Ushiki, Naoko Sato, Takashi Kuroha, Tatsuo Furukawa |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Adolescent medicine.medical_treatment Comorbidity Hematopoietic stem cell transplantation Risk Assessment Prognostic score 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Survival analysis Aged Predictive marker Hematology business.industry Hematopoietic Stem Cell Transplantation Middle Aged Prognosis medicine.disease Survival Analysis Transplantation surgical procedures operative Hematologic Neoplasms 030220 oncology & carcinogenesis Ferritins Female business Risk assessment 030215 immunology |
| Zdroj: | International Journal of Hematology. 108:282-289 |
| ISSN: | 1865-3774 0925-5710 |
| Popis: | The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is a widely used tool for pre-transplant risk assessment. Allogeneic hematopoietic cell transplantation (HCT) is performed on patients with diverse backgrounds, highlighting the need for other predictors to complement the HCT-CI and support bedside decision-making. There is a strong body of evidence supporting the use of pre-transplant serum ferritin (SF) in risk assessments of allogeneic HCT. We additionally found that the Glasgow Prognostic Score (GPS), which assesses inflammatory biomarkers and predicts survival of patients with solid organ malignancies, is a useful predictive marker for overall survival (OS) and non-relapse mortality (NRM) in allogeneic HCT, independent of HCT-CI and SF. In this study, we refined the GPS by adding pre-transplant SF to improve its prognostic ability and enable better stratification; we call this revised index the HCT-specific revised Glasgow Prognostic Score (HCT-GPS). We observed that the HCT-GPS more accurately predicted NRM and early-term OS than the GPS. Moreover, the HCT-GPS provides an independent prognostic factor adjusted for the HCT-CI and disease status, and stratifies patients into four risk groups by OS and NRM. Thus, the HCT-GPS is a useful index for predicting early-term complications after allogeneic HCT in patients with hematopoietic diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink